Wihl J A, Petersen B N, Petersen L N, Gundersen G, Bresson K, Mygind N
J Allergy Clin Immunol. 1985 Jun;75(6):720-7. doi: 10.1016/0091-6749(85)90100-9.
We studied the efficacy and side effects of the H1-antihistamine astemizole in perennial rhinitis. We also defined subgroups of responders and examined the added effect of a steroid spray. Fifty-five adults completed a 10- to 14-week controlled trial. Astemizole reduced the number of sneezes to 41% (p less than 0.001) and the number of nose blowings to 55% (p less than 0.001) of the placebo values. The added use of beclomethasone dipropionate caused a further reduction to 14% (p less than 0.001) and 37% (p less than 0.05), respectively. Nasal blockage was only marginally affected by the antihistamine, but it was reduced to 64% by the steroid spray (p less than 0.001). "Sneezers" responded better to the antihistamine than "blockers," with "nose blowers" in an intermediate position. The effect was equal in allergic and nonallergic patients. Astemizole was completely nonsedative but increased appetite and body weight. An open 1-year study of 17 patients demonstrated that astemizole maintained its efficacy and that further weight gain did not occur. It is concluded that astemizole is a highly effective nonsedative H1-antihistamine suitable for continuous therapy of perennial rhinitis.
我们研究了H1抗组胺药阿司咪唑治疗常年性鼻炎的疗效和副作用。我们还确定了有反应者的亚组,并研究了类固醇喷雾剂的附加作用。55名成年人完成了一项为期10至14周的对照试验。阿司咪唑使打喷嚏次数降至安慰剂组次数的41%(p<0.001),擤鼻涕次数降至55%(p<0.001)。加用二丙酸倍氯米松后,打喷嚏次数和擤鼻涕次数分别进一步降至14%(p<0.001)和37%(p<0.05)。抗组胺药对鼻塞仅有轻微影响,但类固醇喷雾剂使其减少至64%(p<0.001)。“喷嚏型患者”对抗组胺药的反应比“鼻塞型患者”更好,“流涕型患者”处于中间位置。在过敏性和非过敏性患者中,效果相同。阿司咪唑完全无镇静作用,但会增加食欲和体重。一项对17名患者进行的为期1年的开放性研究表明,阿司咪唑保持了其疗效,且体重没有进一步增加。结论是,阿司咪唑是一种高效、无镇静作用的H1抗组胺药,适用于常年性鼻炎的持续治疗。